Summary:
Click image to enlargeEfficacy and safety of tralokinumab administered by an autoinjector in adults and adolescents with modorate-to-severe atopic dermatitis
Qualified Participants Must:
• 12 years of age and over
•
Atopic Dermatitis (eczema) diagnosis of at least a year
•
Inadiquate response to topical treatment
Qualified Participants May Receive:
- All study related care and medication at no cost
- Compensation for tiem and travel of $75 for each completed visit